Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse

Neuroscience

Volumn 154, Issue 4, 2008, Pages 1554-1561

  Palmer, J A ^a   Higuera, E S ^a   Chang, L ^a   Chaplan, S R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

allodynia; endocannabinoid; FAAH; fatty acid amide hydrolase; nociception; thermal injury

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; GABAPENTIN; IBUPROFEN; MORPHINE; N ARACHIDONYLGLYCINE; OL 135;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; THERMAL INJURY;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BURNS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ENZYME INHIBITORS; GLYCERIDES; GLYCINE; MALE; MICE; MICE, CONGENIC; MICE, INBRED C57BL; PAIN; POLYUNSATURATED ALKAMIDES;

EID: 45849112147     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.04.047     Document Type: Article

References (65)

1. Adams I.B., Ryan W., Singer M., Thomas B.F., Compton D.R., Razdan R.K., and Martin B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 273 (1995) 1172-1181
2. Boger D.L., Miyauchi H., Du W., Hardouin C., Fecik R.A., Cheng H., Hwang I., Hedrick M.P., Leung D., Acevedo O., Guimaraes C.R., Jorgensen W.L., and Cravatt B.F. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 48 (2005) 1849-1856
3. Burstein S.H., Huang S.M., Petros T.J., Rossetti R.G., Walker J.M., and Zurier R.B. Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharmacol 64 (2002) 1147-1150
4. Burstein S.H., Rossetti R.G., Yagen B., and Zurier R.B. Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 61 (2000) 29-41
5. Cadas H., Gaillet S., Beltramo M., Venance L., and Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 16 (1996) 3934-3942
6. Chang L., Luo L., Palmer J.A., Sutton S., Wilson S.J., Barbier A.J., Breitenbucher J.G., Chaplan S.R., and Webb M. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148 (2006) 102-113
7. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 (1994) 55-63
8. Clayton N., Marshall F.H., Bountra C., and O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96 (2002) 253-260
9. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98 (2001) 9371-9376
10. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
11. Cravatt B.F., Saghatelian A., Hawkins E.G., Clement A.B., Bracey M.H., and Lichtman A.H. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A 101 (2004) 10821-10826
12. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
13. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., and Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264 (1999) 258-267
14. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., and Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
15. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., and Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99 (2002) 10819-10824
16. Dinh T.P., Kathuria S., and Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66 (2004) 1260-1264
17. Finn D.P., and Chapman V. Cannabinoids as analgesic agents: evidence from in vivo studies. Curr Neuropharmacol 2 (2004) 75-89
18. Goparaju S.K., Ueda N., Taniguchi K., and Yamamoto S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57 (1999) 417-423
19. Goparaju S.K., Ueda N., Yamaguchi H., and Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 422 (1998) 69-73
20. Guindon J., LoVerme J., De Lean A., Piomelli D., and Beaulieu P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides?. Eur J Pharmacol 550 (2006) 68-77
21. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11 (1991) 563-583
22. Hohmann A.G., Farthing J.N., Zvonok A.M., and Makriyannis A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308 (2004) 446-453
23. Huang S.M., Bisogno T., Petros T.J., Chang S.Y., Zavitsanos P.A., Zipkin R.E., Sivakumar R., Coop A., Maeda D.Y., De Petrocellis L., Burstein S., Di Marzo V., and Walker J.M. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 276 (2001) 42639-42644
24. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., Vanderah T.W., Lai J., Porreca F., Makriyannis A., and Malan Jr. T.P. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100 (2003) 10529-10533
25. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., and Malan Jr. T.P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102 (2005) 3093-3098
26. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., and Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147 (2006) 281-288
27. Jhaveri M.D., Richardson D., Kendall D.A., Barrett D.A., and Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26 (2006) 13318-13327
28. Jun J.H., and Yaksh T.L. The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 86 (1998) 348-354
29. Karlsson M., Contreras J.A., Hellman U., Tornqvist H., and Holm C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272 (1997) 27218-27223
30. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., and Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 (2003) 76-81
31. Kuschinsky K., and Hornykiewicz O. Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. Eur J Pharmacol 26 (1974) 41-50
32. Leung D., Du W., Hardouin C., Cheng H., Hwang I., Cravatt B.F., and Boger D.L. Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. Bioorg Med Chem Lett 15 (2005) 1423-1428
33. Lichtman A.H., Hawkins E.G., Griffin G., and Cravatt B.F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302 (2002) 73-79
34. Lichtman A.H., Leung D., Shelton C.C., Saghatelian A., Hardouin C., Boger D.L., and Cravatt B.F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311 (2004) 441-448
35. Lichtman A.H., Shelton C.C., Advani T., and Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 (2004) 319-327
36. Mailleux P., and Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-668
37. Maione S., De Petrocellis L., de Novellis V., Moriello A.S., Petrosino S., Palazzo E., Rossi F.S., Woodward D.F., and Di Marzo V. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150 (2007) 766-781
38. Malan Jr. T.P., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., and Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 (2001) 239-245
39. Malkmus S., Lu X., Bartfai T., Yaksh T.L., and Hua X.Y. Increased hyperalgesia after tissue injury and faster recovery of allodynia after nerve injury in the GalR1 knockout mice. Neuropeptides 39 (2005) 217-221
40. Matsuda L.A., Bonner T.I., and Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327 (1993) 535-550
41. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
42. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., and Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
43. Mogil J.S., Wilson S.G., Bon K., Lee S.E., Chung K., Raber P., Pieper J.O., Hain H.S., Belknap J.K., Hubert L., Elmer G.I., Chung J.M., and Devor M. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 80 (1999) 67-82
44. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
45. Nackley A.G., Makriyannis A., and Hohmann A.G. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119 (2003) 747-757
46. Nozaki-Taguchi N., and Yaksh T.L. A novel model of primary and secondary hyperalgesia after mild thermal injury in the rat. Neurosci Lett 254 (1998) 25-28
47. Rethy C.R., Smith C.B., and Villarreal J.E. Effects of narcotic analgesics upon the locomotor activity and brain catecholamine content of the mouse. J Pharmacol Exp Ther 176 (1971) 472-479
48. Richardson J.D., Kilo S., and Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 (1998) 111-119
49. Russo R., Loverme J., La Rana G., Compton T.R., Parrott J., Duranti A., Tontini A., Mor M., Tarzia G., Calignano A., and Piomelli D. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322 (2007) 236-242
50. Scott D.A., Wright C.E., and Angus J.A. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109 (2004) 124-131
51. Shi T.J., Hua X.Y., Lu X., Malkmus S., Kinney J., Holmberg K., Wirz S., Ceccatelli S., Yaksh T., Bartfai T., and Hokfelt T. Sensory neuronal phenotype in galanin receptor 2 knockout mice: focus on dorsal root ganglion neurone development and pain behaviour. Eur J Neurosci 23 (2006) 627-636
52. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., and Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270 (1994) 219-227
53. Sokal D.M., Elmes S.J., Kendall D.A., and Chapman V. Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 45 (2003) 404-411
54. Succar R., Mitchell V.A., and Vaughan C.W. Actions of N-arachidonyl-glycine in a rat inflammatory pain model. Mol Pain 3 (2007) 24
55. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 (1995) 89-97
56. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
57. Valenzano K.J., Tafesse L., Lee G., Harrison J.E., Boulet J.M., Gottshall S.L., Mark L., Pearson M.S., Miller W., Shan S., Rabadi L., Rotshteyn Y., Chaffer S.M., Turchin P.I., Elsemore D.A., Toth M., Koetzner L., and Whiteside G.T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48 (2005) 658-672
58. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
59. Walker J.M., and Huang S.M. Cannabinoid analgesia. Pharmacol Ther 95 (2002) 127-135
60. Walker J.M., Huang S.M., Strangman N.M., Tsou K., and Sanudo-Pena M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96 (1999) 12198-12203
61. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23 (2003) 1398-1405
62. Willoughby K.A., Moore S.F., Martin B.R., and Ellis E.F. The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282 (1997) 243-247
63. Wise L.E., Cannavacciulo R., Cravatt B.F., Martin B.F., and Lichtman A.H. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology 54 (2008) 181-188
64. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., and O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17 (2003) 2750-2754
65. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110